RapiScan r (regadenoson) is the first selective receptor adenosine A2A agonist.

London, February 2011. Rapidscan Pharma Solutions (RPS) us Ltd has announced that it has received last Friday permission marketing for Rapiscan r (regadenoson) – a coronary vasodilator selective for use as a pharmacologic stress agent in diagnosis of coronary artery disease (CAD) – the most common single cause of death and disability in Europe [1]. RapiScan is administered as a bolus injection not based on the weight and is the first and only receptor agonist selective adenosine A2A on having license for its use in this indication.

Diagnosis of CAD used the image of perfusion of myocardial infarction (MPI) to identify areas of poor in heart blood flow while resting or practice exercise. Often ask patients to do exercises in a wheel of walking or biking, but almost half of the patients are not able to exercise properly. RapiScan stimulates the effects of the exercise by increasing temporarily the flow of blood through the arteries of the heart, providing an option for these patients. Unlike the older agents, Rapiscan needs no adjustment of the dose for the variation in body weight [2] and its method of bolus dosage is fast (only 10 seconds), reducing the need for a pump infusion and its implementation to point.

The founder, CEO and Managing Director of Rapidscan Pharma Solutions, Dr. Brent Blackburn, said: “I am very excited for Rapiscan Europe.” RapiScan is designed to address specifically the needs of patients and health professionals to perform tests MPI. “It is easier to use and is tolerated better than older agents.”

Each year, more than 4 million Europeans die from diseases of the heart and blood vessels [1], accounting for about half of the total mortality in Europe [1]. Accurate diagnosis is vital in identifying patients who are suitable for intensive medical intervention with more than 1.5 million Europeans undergo MPI annual testing.

Regadenoson was released in United States in the year 2008 after performing clinical trials in more than 2,000 patients with known CAD or suspect [3,4]. Currently, regadenoson is used more broadly as agents against pharmacological stress in United States, and more than 3 million patients have received you.

More about regadenoson

Regadenoson is an agonist receptor selective A2A adenosine approved as an agent of pharmacologic stress in radionuclide MPI in patients unable to undergo adequate exercise testing. Regadenoson was discovered and developed by CV Therapeutics and received FDA approval in April 2008 and also received the US License Commission by the European medicines Agecia in September 2010.

About Rapidscan Pharma Solutions (RPS)

Rapidscan Pharma Solutions Inc, headquartered in United States, was created in the year 2010 through its general director and Chief Executive Officer, Dr. Brent Blackburn. In September 2010 RPS Inc. licensed the rights for the development, manufacture and marketing of regadenoson from Gilead Sciences Inc. for Europe, Japan, Australia, New Zealand and Israel. Its European subsidiary, RPS us Ltd, is responsible for the marketing of regadenoson in Europe. Dr. Blackburn has previously worked with CV Therapeutics and was a leading member of the team that discovered and developed regadenoson United States and Europe.

–
Referencia:

[1] Scholte op Reimer WJM, Gitt AK, Boersma E, Simoons ML (eds.). Cardiovascular Diseases in Europe. Euro Heart Survey – 2006. Sophia Antipolis; European Society of Cardiology; 2006

[2]. RapiScan Summary of Product Characteristics. Gilead Sciences; September 2010.

[3]. Cerqueira MD, Nguyen P, Staehr P et to, on behalf of the ADVANCE MPI Trial Investigators. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist Rapiscan versus adenosine: integrated ADVANCE MPI trial results. J Am Coll Cardiol 2008; 1: 307-316

[4]. Iskandrian AE, Bateman TM, Belardinelli L, et to the. Adenosine versus Rapiscan comparative evaluation in many imaging myocardial: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007; 14: 645-658